NH - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.9
| Stock Code | NH | Market Cap | 38,198 Cr. | Current Price | 1,869 ₹ | High / Low | 2,372 ₹ |
| Stock P/E | 71.1 | Book Value | 127 ₹ | Dividend Yield | 0.24 % | ROCE | 19.8 % |
| ROE | 22.5 % | Face Value | 10.0 ₹ | DMA 50 | 1,854 ₹ | DMA 200 | 1,801 ₹ |
| Chg in FII Hold | -1.12 % | Chg in DII Hold | 1.23 % | PAT Qtr | 202 Cr. | PAT Prev Qtr | 109 Cr. |
| RSI | 48.7 | MACD | 5.40 | Volume | 2,62,641 | Avg Vol 1Wk | 2,95,983 |
| Low price | 1,564 ₹ | High price | 2,372 ₹ | PEG Ratio | 2.57 | Debt to equity | 0.76 |
| 52w Index | 37.8 % | Qtr Profit Var | 26.4 % | EPS | 24.6 ₹ | Industry PE | 45.6 |
📊 Analysis: NH shows strong profitability metrics with ROE at 22.5% and ROCE at 19.8%, reflecting efficient capital use. Debt-to-equity at 0.76 is moderate, manageable for growth. EPS of 24.6 ₹ and PAT growth (202 Cr. vs 109 Cr.) highlight earnings momentum. However, valuation is stretched with P/E at 71.1 compared to industry average of 45.6, and PEG ratio at 2.57 suggests growth is already priced in. Dividend yield of 0.24% is modest. Technicals show neutral momentum (RSI 48.7, MACD positive), with price consolidating near DMA 50 (1,854 ₹) and DMA 200 (1,801 ₹).
💡 Entry Zone: Ideal entry lies between ₹1,750 – ₹1,850, closer to DMA 200 support, offering valuation comfort and better risk-reward alignment.
⏳ Exit / Holding Strategy: Existing holders should maintain a medium-to-long horizon (3–5 years) given strong efficiency metrics and earnings growth. Consider partial profit booking near ₹2,250–2,350 resistance zone. Exit fully only if valuations expand further without earnings support or if institutional selling pressure increases.
Positive
- ✅ Strong ROE (22.5%) and ROCE (19.8%) highlight efficient capital allocation
- ✅ EPS of 24.6 ₹ supports earnings visibility
- ✅ PAT growth of 26.4% shows operational improvement
- ✅ Moderate debt-to-equity ratio (0.76)
Limitation
- ⚠️ High P/E (71.1 vs industry 45.6) indicates premium valuation
- ⚠️ PEG ratio of 2.57 suggests limited upside relative to growth
- ⚠️ Dividend yield at 0.24% is modest
- ⚠️ Decline in FII holdings (-1.12%) shows reduced foreign investor confidence
Company Negative News
- 📉 Reduction in FII holdings (-1.12%) signals cautious foreign sentiment
Company Positive News
- 📈 Quarterly PAT improved to 202 Cr. from 109 Cr.
- 📈 DII holdings increased (+1.23%), reflecting domestic institutional support
Industry
- 🏭 Industry P/E at 45.6 highlights NH’s premium valuation
- 🏭 Healthcare sector benefits from rising demand and structural growth opportunities
Conclusion
🔎 NH is a fundamentally strong healthcare company with robust efficiency metrics and earnings growth, but valuations are stretched. Best suited for accumulation near ₹1,750–₹1,850. Hold for 3–5 years, booking profits near resistance levels, while monitoring institutional flows and valuation sustainability.
Would you like me to extend this into a peer benchmarking report comparing NH with other healthcare companies, or a growth drivers analysis highlighting catalysts like hospital expansion and rising healthcare demand?